Does the media refer more to MDGL or VKTX?

In the previous week, Viking Therapeutics had 3 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 9 mentions for Viking Therapeutics and 6 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 1.25 beat Viking Therapeutics' score of 0.90 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LLY or VKTX?

In the previous week, Eli Lilly and Company had 110 more articles in the media than Viking Therapeutics. MarketBeat recorded 119 mentions for Eli Lilly and Company and 9 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.90 beat Eli Lilly and Company's score of 0.89 indicating that Viking Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eli Lilly and Company 67 Very Positive mention(s) 25 Positive mention(s) 14 Neutral mention(s) 4 Negative mention(s) 8 Very Negative mention(s) Positive Viking Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PFE or VKTX?

In the previous week, Pfizer had 65 more articles in the media than Viking Therapeutics. MarketBeat recorded 74 mentions for Pfizer and 9 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.90 beat Pfizer's score of 0.89 indicating that Viking Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 42 Very Positive mention(s) 11 Positive mention(s) 10 Neutral mention(s) 5 Negative mention(s) 5 Very Negative mention(s) Positive Viking Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BMRN or VKTX?

In the previous week, BioMarin Pharmaceutical had 22 more articles in the media than Viking Therapeutics. MarketBeat recorded 31 mentions for BioMarin Pharmaceutical and 9 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.90 beat BioMarin Pharmaceutical's score of 0.74 indicating that Viking Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 11 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VKTX or EXEL?

In the previous week, Exelixis had 1 more articles in the media than Viking Therapeutics. MarketBeat recorded 10 mentions for Exelixis and 9 mentions for Viking Therapeutics. Exelixis' average media sentiment score of 1.07 beat Viking Therapeutics' score of 0.90 indicating that Exelixis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Viking Therapeutics (VKTX) Competitors

$34.36 -1.62 (-4.50%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$34.40 +0.05 (+0.13%)

As of 08/20/2026 06:42 PM Eastern

Compare

VKTX vs. MDGL, LLY, PFE, BMRN, and EXEL

Should you buy Viking Therapeutics stock or one of its competitors? Viking Therapeutics's main competitors and comparable companies include Madrigal Pharmaceuticals (MDGL), Eli Lilly and Company (LLY), Pfizer (PFE), BioMarin Pharmaceutical (BMRN), and Exelixis (EXEL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Viking Therapeutics compare to Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

Madrigal Pharmaceuticals has a beta of -1.01, meaning that its stock price is 201% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

Madrigal Pharmaceuticals has higher revenue and earnings than Viking Therapeutics. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40M	12.51	-$288.28M	-$12.89	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A

In the previous week, Viking Therapeutics had 3 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 9 mentions for Viking Therapeutics and 6 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 1.25 beat Viking Therapeutics' score of 0.90 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Madrigal Pharmaceuticals currently has a consensus target price of $689.93, indicating a potential upside of 32.91%. Viking Therapeutics has a consensus target price of $96.63, indicating a potential upside of 181.21%. Given Viking Therapeutics' higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Viking Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Madrigal Pharmaceuticals' return on equity of -56.65% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
Viking Therapeutics	N/A	-94.56%	-82.75%

98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are held by insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Madrigal Pharmaceuticals beats Viking Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Viking Therapeutics compare to Eli Lilly and Company?

Eli Lilly and Company (NYSE:LLY) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Eli Lilly and Company has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eli Lilly and Company	$65.18B	18.01	$20.64B	$29.80	41.84
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A

In the previous week, Eli Lilly and Company had 110 more articles in the media than Viking Therapeutics. MarketBeat recorded 119 mentions for Eli Lilly and Company and 9 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.90 beat Eli Lilly and Company's score of 0.89 indicating that Viking Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eli Lilly and Company	67 Very Positive mention(s)	25 Positive mention(s)	14 Neutral mention(s)	4 Negative mention(s)	8 Very Negative mention(s)	Positive
Viking Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

82.5% of Eli Lilly and Company shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 0.1% of Eli Lilly and Company shares are held by company insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Eli Lilly and Company has a net margin of 33.53% compared to Viking Therapeutics' net margin of 0.00%. Eli Lilly and Company's return on equity of 97.83% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eli Lilly and Company	33.53%	97.83%	23.23%
Viking Therapeutics	N/A	-94.56%	-82.75%

Eli Lilly and Company currently has a consensus price target of $1,292.18, indicating a potential upside of 3.63%. Viking Therapeutics has a consensus price target of $96.63, indicating a potential upside of 181.21%. Given Viking Therapeutics' higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Eli Lilly and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eli Lilly and Company	1 Sell rating(s)	4 Hold rating(s)	24 Buy rating(s)	1 Strong Buy rating(s)	2.83
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Eli Lilly and Company has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

Summary

Eli Lilly and Company beats Viking Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Viking Therapeutics compare to Pfizer?

Pfizer (NYSE:PFE) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Pfizer has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.53	$7.77B	$0.76	36.62
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A

Pfizer has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

68.4% of Pfizer shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 0.6% of Pfizer shares are held by insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Pfizer presently has a consensus target price of $28.28, indicating a potential upside of 1.61%. Viking Therapeutics has a consensus target price of $96.63, indicating a potential upside of 181.21%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Pfizer had 65 more articles in the media than Viking Therapeutics. MarketBeat recorded 74 mentions for Pfizer and 9 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.90 beat Pfizer's score of 0.89 indicating that Viking Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	42 Very Positive mention(s)	11 Positive mention(s)	10 Neutral mention(s)	5 Negative mention(s)	5 Very Negative mention(s)	Positive
Viking Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Pfizer has a net margin of 6.80% compared to Viking Therapeutics' net margin of 0.00%. Pfizer's return on equity of 19.63% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	6.80%	19.63%	8.46%
Viking Therapeutics	N/A	-94.56%	-82.75%

Summary

Pfizer beats Viking Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Viking Therapeutics compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

In the previous week, BioMarin Pharmaceutical had 22 more articles in the media than Viking Therapeutics. MarketBeat recorded 31 mentions for BioMarin Pharmaceutical and 9 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.90 beat BioMarin Pharmaceutical's score of 0.74 indicating that Viking Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	11 Very Positive mention(s)	5 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

BioMarin Pharmaceutical has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	4.07	$348.90M	$0.37	182.92
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A

BioMarin Pharmaceutical presently has a consensus target price of $88.83, suggesting a potential upside of 31.24%. Viking Therapeutics has a consensus target price of $96.63, suggesting a potential upside of 181.21%. Given Viking Therapeutics' higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.75
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

BioMarin Pharmaceutical has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Viking Therapeutics' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Viking Therapeutics	N/A	-94.56%	-82.75%

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 0.7% of BioMarin Pharmaceutical shares are held by insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

BioMarin Pharmaceutical beats Viking Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Viking Therapeutics compare to Exelixis?

Viking Therapeutics (NASDAQ:VKTX) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Viking Therapeutics presently has a consensus price target of $96.63, indicating a potential upside of 181.21%. Exelixis has a consensus price target of $50.07, indicating a potential downside of 6.75%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viking Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Exelixis	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.30

In the previous week, Exelixis had 1 more articles in the media than Viking Therapeutics. MarketBeat recorded 10 mentions for Exelixis and 9 mentions for Viking Therapeutics. Exelixis' average media sentiment score of 1.07 beat Viking Therapeutics' score of 0.90 indicating that Exelixis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Viking Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market.

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by insiders. Comparatively, 2.6% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Exelixis has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
Exelixis	$2.32B	5.73	$782.57M	$3.18	16.88

Exelixis has a net margin of 35.33% compared to Viking Therapeutics' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-94.56%	-82.75%
Exelixis	35.33%	42.17%	31.76%

Summary

Exelixis beats Viking Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Viking Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VKTX vs. The Competition

Export

Metric	Viking Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.20B	$4.07B	$7.37B	$12.86B
Dividend Yield	N/A	3.64%	2.53%	10.69%
P/E Ratio	-7.37	11.53	268.65	24.05
Price / Sales	N/A	1,323.70	610.61	88.12
Price / Cash	N/A	103.92	78.13	53.57
Price / Book	9.82	17.09	13.07	6.15
Net Income	-$359.64M	-$12.52M	$3.46B	$347.39M
7 Day Performance	3.53%	1.79%	1.10%	-0.86%
1 Month Performance	-9.46%	5.14%	3.98%	1.13%
1 Year Performance	33.90%	58.46%	26.52%	19.65%

Viking Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VKTX Viking Therapeutics	3.3699 of 5 stars	$34.36 -4.5%	$96.63 +181.2%	+33.7%	$4.20B	N/A	N/A	20	Positive News Analyst Upgrade
MDGL Madrigal Pharmaceuticals	3.809 of 5 stars	$536.20 +0.2%	$689.93 +28.7%	+32.5%	$12.37B	$958.40M	N/A	90	Positive News Insider Trade
LLY Eli Lilly and Company	4.8073 of 5 stars	$1,219.57 +0.4%	$1,292.18 +6.0%	+76.9%	$1.14T	$79.67B	40.93	50,000	Trending News Insider Trade
PFE Pfizer	3.5488 of 5 stars	$26.29 -1.2%	$28.28 +7.6%	+9.7%	$151.73B	$62.58B	34.59	75,000	Trending News Options Volume
BMRN BioMarin Pharmaceutical	4.8187 of 5 stars	$70.24 +1.0%	$88.00 +25.3%	+16.8%	$13.46B	$3.22B	189.84	3,221	Trending News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VKTX) was last updated on 8/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viking Therapeutics (VKTX) Competitors

VKTX vs. MDGL, LLY, PFE, BMRN, and EXEL

How does Viking Therapeutics compare to Madrigal Pharmaceuticals?

Summary

How does Viking Therapeutics compare to Eli Lilly and Company?

Summary

How does Viking Therapeutics compare to Pfizer?

Summary

How does Viking Therapeutics compare to BioMarin Pharmaceutical?

Summary

How does Viking Therapeutics compare to Exelixis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VKTX vs. The Competition

Viking Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Viking Therapeutics (VKTX) Competitors

VKTX vs. MDGL, LLY, PFE, BMRN, and EXEL

How does Viking Therapeutics compare to Madrigal Pharmaceuticals?

Which has more risk & volatility, MDGL or VKTX?

Which has better valuation & earnings, MDGL or VKTX?

Does the media refer more to MDGL or VKTX?

Do analysts recommend MDGL or VKTX?

Is MDGL or VKTX more profitable?

Do insiders & institutionals hold more shares of MDGL or VKTX?

Summary

How does Viking Therapeutics compare to Eli Lilly and Company?

Which has preferable valuation and earnings, LLY or VKTX?

Does the media prefer LLY or VKTX?

Do insiders & institutionals hold more shares of LLY or VKTX?

Is LLY or VKTX more profitable?

Do analysts prefer LLY or VKTX?

Which has more volatility and risk, LLY or VKTX?

Summary

How does Viking Therapeutics compare to Pfizer?

Which has better earnings & valuation, PFE or VKTX?

Which has more risk & volatility, PFE or VKTX?

Do institutionals and insiders hold more shares of PFE or VKTX?

Do analysts prefer PFE or VKTX?

Does the media prefer PFE or VKTX?

Is PFE or VKTX more profitable?

Summary

How does Viking Therapeutics compare to BioMarin Pharmaceutical?

Does the media prefer BMRN or VKTX?

Which has higher earnings & valuation, BMRN or VKTX?

Do analysts recommend BMRN or VKTX?

Which has more volatility & risk, BMRN or VKTX?

Is BMRN or VKTX more profitable?

Do insiders & institutionals hold more shares of BMRN or VKTX?

Summary

How does Viking Therapeutics compare to Exelixis?

Do analysts prefer VKTX or EXEL?

Does the media favor VKTX or EXEL?

Which has more risk & volatility, VKTX or EXEL?

Do insiders and institutionals hold more shares of VKTX or EXEL?

Which has stronger earnings & valuation, VKTX or EXEL?

Is VKTX or EXEL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VKTX vs. The Competition

Viking Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools